Literature DB >> 3103768

Rapid progression of a growth hormone producing tumour during dopamine agonist treatment.

K Heidvall, A L Hulting.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3103768      PMCID： PMC1245581          DOI： 10.1136/bmj.294.6571.546

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  Long-term treatment of acromegaly with bromocriptine.

Authors:  J A Wass; M O Thorner; D V Morris; L H Rees; A S Mason; A E Jones; G M Besser
Journal:  Br Med J       Date:  1977-04-02

2.  Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats.

Authors:  D K Sarkar; P E Gottschall; J Meites
Journal:  Endocrinology       Date:  1984-10       Impact factor: 4.736

3.  The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly.

Authors:  S W Lamberts; A Liuzzi; P G Chiodini; S Verde; J G Klijn; J C Birkenhäger
Journal:  Eur J Clin Invest       Date:  1982-04       Impact factor: 4.686

4.  Bomocriptine treatment of patients with acromegaly resistant to conventional therapy.

Authors:  R Pelkonen; R Ylikahri; S L Karonen
Journal:  Clin Endocrinol (Oxf)       Date:  1980-03       Impact factor: 3.478
  4 in total
  2 in total

Review 1.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

2.  Significance of recombinant human growth hormone therapy in promoting growth and development of children with idiopathic short stature.

Authors:  Wenbiao Han; Jing Zhang; Tao Song; Yanni Han
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.